Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 93Small Cell Lung Carcinoma 74Neuroblastoma 44Carcinoma, Ovarian Epithelial 43Fallopian Tube Neoplasms 41Lung Neoplasms 39Neoplasms 29Uterine Cervical Neoplasms 26Leukemia 20Brain Neoplasms 18Leukemia, Myeloid, Acute 17Recurrence 16Sarcoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasm Metastasis 13Lymphoma 12Central Nervous System Neoplasms 12Retinoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Sarcoma, Ewing 10Unspecified Adult Solid Tumor, Protocol Specific 8Neuroectodermal Tumors, Primitive, Peripheral 8Myelodysplastic Syndromes 8Medulloblastoma 8Endometrial Neoplasms 8Burkitt Lymphoma 8Lymphoma, Follicular 7Leukemia, Myelomonocytic, Chronic 7Blast Crisis 7

Interventions

Etoposide 3Carboplatin 3Paclitaxel 2sintilimab 1pembrolizumab 1olaparib 1ceralasertib 1atezolizumab 1apatinib 1anlotinib 1Topotecan 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × SCLC × Topotecan × Clear all
NCT06616532 2026-05-22

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Biotheus Inc.

Phase 3 Active not recruiting
404 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡